In August 2020, the article 'Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P1) Modulators: Optimization of the PK, PD, and Safety Profiles' describing efforts aimed at increasing the in vivo potency and reducing the elimination half-life among drug candidates against Multiple Sclerosis (MS) was published.

"Compound 3d" was developed as a prodrug that is phosphorylated in vivo to form a potent sphingosine-1-phosphate receptor (S1P1) modulator and possess a shorter predicted human half-life (5 days). "Compound 3d" contains amino-cyclopentyl-methanol moiety in its backbone.

We have made a set of compounds, with analogs of such part – the perfect start for your research!